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ABSTRACT  
   
Flavivirus infections are emerging as significant threats to human health around 
the globe. Among them West Nile(WNV) and Dengue Virus (DV) are the most prevalent 
in causing human disease with WNV outbreaks occurring in all areas around the world 
and DV epidemics in more than 100 countries. WNV is a neurotropic virus capable of 
causing meningitis and encephalitis in humans. Currently, there are no therapeutic 
treatments or vaccines available. The expanding epidemic of WNV demands studies that 
develop efficacious therapeutics and vaccines and produce them rapidly and 
inexpensively. In response, our lab developed a plant-derived monoclonal antibody 
(mAb) (pHu-E16) against DIII (WNV antigen) that is able to neutralize and prevent mice 
from lethal infection. However, this drug has a short window of efficacy due to pHu-
E16's inability to cross the Blood Brain Barrier (BBB) and enter the brain. Here, we 
constructed a bifunctional diabody, which couples the neutralizing activity of E16 and 
BBB penetrating activity of 8D3 mAb. We also produced a plant-derived E16 scFv-CH1-3 
variant with equivalent specific binding as the full pHu-E16 mAb, but only requiring one 
gene construct for production. Furthermore, a WNV vaccine based on plant-derived DIII 
was developed showing proper folding and potentially protective immune response in 
mice. DV causes severe hemorrhaging diseases especially in people exposed to secondary 
DV infection from a heterotypic strain. It is hypothesized that sub-neutralizing cross-
reactive antibodies from the first exposure aid the second infection in a process called 
antibody-dependent enhancement (ADE). ADE depends on the ability of mAb to bind Fc 
receptors (FcγRs), and has become a major roadblock for developing mAb-based 
therapeutics against DV. We aim to produce an anti-Dengue mAb (E60) in different 
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glycoengineered plant lines that exhibit reduced/differential binding to FcγRs, therefore, 
reducing or eliminating ADE. We have successfully cloned the molecular constructs of 
E60, and expressed it in two plant lines with different glycosylation patterns. We 
demonstrated that both plant-derived E60 mAb glycoforms retained specific recognition 
and neutralization activity against DV. Overall, our study demonstrates great strives to 
develop efficacious therapeutics and potent vaccine candidates against Flaviviruses in 
plant expression systems. 
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CHAPTER 1 
OVERVIEW OF FLAVIVIRUSES 
 Flavivirus is one of the genera included in the Flaviviridae family that also 
includes the genera Hepacivirus and Pestivirus. Further subdivision of the Flavivirus 
genus is based on cross-neutralizing test results in eight antigenic complexes including 
Dengue, Japanese encephalitis, Tick-borne encephalitis, Rio Bravo, Tyuleniy, Ntaya, 
Uganda S, and Modoc antigenic groups (Calisher, 1989). Overall, within Flavivirus there 
are over 70 different viruses , and most noteworthy to human health include yellow fever 
virus (YFV), Dengue virus (DV), Japanese encephalitis virus (JEV), West Nile virus 
(WNV) and tick-borne encephalitis virus (TBEV) (Heinz, 2012). These viruses can cause 
a broad range of disease from mild discomfort to hemorrhagic fevers, flaccid paralysis 
and even encephalitis (Gould 2008).  Other members of this genus are rarely encountered 
by humans and their reported case numbers are relatively small. Nevertheless, they have 
the potential to cause severe disease in humans (Heinz, 2012). Most of these viruses are 
arboviruses with YFV, DV, JEV, and WNV being transmitted by mosquitoes; and TBEV 
being transmitted by ticks. Humans are considered to be the "dead-end" or incidental host 
to these viruses, due to humans' inability to maintain high enough viremia titers to re-
infect arthropod vectors. However, cases of human to human transmission, by means of 
blood transfusions and organ transplant have been reported (Nicole, 2012).  
 Flaviviruses are enveloped icosahedral viruses with a diameter of ≈500 Å and 
have a single positive strand RNA genome of 10.7 kb (Kuhn, 2002). The genome 
contains an open reading frame (ORF) that codes three structural proteins near the N-
terminus along with seven non-structural proteins (NS) near the C-terminus. The three 
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major structural proteins encoded in the genome are the capsid protein (CP), pre-
membrane/membrane protein (preM/M) and envelope protein (E).  The CP (100 aa) is a 
dimer which surrounds positive strand RNA, housing the genome and creating the 
nucleocapsid core. Little is known about the preM/M protein (166/75 aa) but it is 
speculated to have a chaperone protein function for E protein, as well as serving  as an 
indicator distinguishing the maturation transition from immature form to the infectious 
form of the viral particle (preM to M) (Zhang, 2004). The E protein (495 aa) is a dimer 
with each monomer made up of three domains (domain (D) I, II, and III). It is responsible 
for the binding of virus to cellular receptors, mediating the entry for virus, and cell 
membrane fusion (Chamber, 1990). DI carries out a structural rearrangement function in 
acidic conditions, DII is responsible for virus to cell membrane fusion due to its 
hydrophobic peptide region, and DIII serves as the binding site for cellular receptors with 
its C-terminal immunoglobulin (Ig)-like structure. The seven NS protein encoded in the 
genome are NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5. They function mainly on 
RNA genome replication and viral protein synthesis. Within the seven NS proteins, NS3 
and NS5 are the most conserved proteins and they carry out the main functions while the 
rest of the NS proteins act as activators or support molecules. NS3 has bifunctional 
activity when coupled with NS2B, providing both protease and possibly helicase activity 
(Chamber, 1990; Pastorino, 2010). NS5 serves as a viral RNA polymerase with methyl-
transferase activity (Chamber, 1990; Pastorino, 2010).  
 Flaviviruses follow a similar viral life cycle as other viruses. The cycle begins 
with attachment of the virion onto the surface of a host cell. This specific binding induces 
a receptor-mediated (αvβ3 integrin and laminin-binding protein) endocytosis, granting 
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viral entry into the cell (Brinton, 2014). The low pH within the endosomal vesicle 
triggers conformational changes of the E protein, exposing Domain III. As a result, the 
viral and cell membranes fuse together (Thompson, 2009), nucleocapsid disassembles, 
and the RNA genome is released into the cytoplasm of the cell allowing both replication 
and translation of the genome to occur. Translation of the positive-sense RNA results in a 
single polyprotein with all 10 viral proteins being synthesized. Further processing 
incorporates host and viral proteases to cleave polyprotein into the ten mature proteins 
(Shi, 1996). The NS proteins (specifically NS5) construct a viral replication complex 
which uses the positive sense genome to generate complementary negative-sense 
intermediate strands (Chamber, 1990). The intermediate strands act as templates to 
synthesize the positive sense viral genome. Viral assembly of the viral RNA genome and 
structural proteins occurs on the surface of the endoplasmic reticulum (ER). The 
immature virions are transported through the trans-Golgi network (TGN) and pre-M is 
cleaved by the host protease furin, inducing rearrangement of E protein and activating the 
infectious form of the viral particle (Pastorino, 2010). After maturation, the virion along 
with subviral particles (that only contain M and E protein) are exocytosed and ready to 
infect other cells. 
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CHAPTER 2 
WEST NILE VIRUS 
1. Introduction 
1.1 General Overview 
 West Nile virus (WNV) is an arbovirus that belongs to the Flavivirus genus of the 
Flaviviridae family. This neurotropic virus falls within the Japanese encephalitis virus 
antigenic complex; along with Murray Valley encephalitis virus, St Louis encephalitis 
virus, and Kunjin virus (Calisher, 1988). The virus is enveloped and icosahedral with a 
single positive stranded RNA genome (10.7 kb). Around the world, two lineages of WNV 
exist with the first lineage commonly responsible for avian, human, and equine disease. 
1.2 Signs and Symptoms  
 In most cases, WNV infected patients are asymptomatic. Furthermore, 3-14 days 
after being bitten by an infected mosquito, only 20-30% of patients develop mild and 
acute symptoms (West Nile Fever) for which generally last 3-6 days (Goodman, 2012). 
Mild symptoms include a sudden appearance of flu-like symptoms, which may include 
rhinorrhea, cough, sore throat, malaise, fever, myalgia, nausea, vomiting, anorexia, eye 
pain, headache, and rash. In rare cases (less than 1%), severe neurological symptoms can 
arise with a 10% fatality rate (Peterson, 2003, CDC.gov).  Severe neurological symptoms 
include encephalitis and meningitis with more than 50% presenting acute flaccid 
paralysis or other permanent neurological injury due to neurons inability to regenerate. 
Susceptibility of developing severe neurological symptoms increases with age (especially 
among those 60 to 89 years of age) with all ages and genders appearing to be equally 
susceptible to WNV infection (Hayes, CDC fig). Other than advanced age, people who 
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are immunosuppressed or suffer from other predispositions can develop severe 
neurological symptoms (Petersen, 2003). Predispositions include genetic mutations, such 
as C—C chemokine receptor type 5 (CCR5) and 2–5 oligoadenylate synthethase (OAS) 
mutations, or even hypertension, diabetes, and smoking (Sips, 2012; Diamond, 2009a). 
1.3. Treatment and Prevention 
 Currently, there are no approved vaccines or specific antiviral treatments for 
WNV infections. People that develop symptoms rely on anodynes and supportive 
treatment until the infection is cleared.  Treatment of WNV infection has been of growing 
importance with considerable research looking into immune γ-globulin, interferon α-2b, 
and antisense oligomers along with others as potential therapeutic treatments (Diamond, 
2009b). Preliminary in vitro results of several candidates have shown prophylaxis, 
however in vivo and therapeutic studies have not had the same efficacy (Diamond, 
2009b). Aside from the previous candidates, monoclonal antibodies (mAbs) therapies 
have also been explored as potential therapeutic treatments against viral infections with 
E16 showing both prophylaxis and therapeutic activity (Both, 2013; Kaufmann, 2006). 
1.4. Ecology and Life Cycle 
 WNV is usually maintained and amplified in enzootic cycles between  female 
mosquito vectors and bird hosts; predominantly, Culex (Cx) species of mosquitoes (e.g. 
Cx pipiens, Cx tarsalis, Cx salinarius, Cx quinquefasciatus) and passerine birds, although 
other species of mosquitoes and birds have been seen to carry the virus (Gea-Banacloche, 
2004; Farajollahi, 2011).  The female gender of Culex mosquito is the primary vector of 
many viruses, including WNV, due to the higher nutrient requirements needed for the 
energy demands of reproduction. While feeding on a blood meal they transfer saliva, 
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anticoagulants, and other pathogens into the host animal (Tolle, 2009). In most cases the 
host animals are birds, but in some instances other animals, including humans, can 
become an incidental/ "dead end" host. Birds are natural reservoirs for WNV with many 
avian species able to survive infection, become immune, and develop high-titer viremias 
to transmit to other feeding mosquitoes (Campbell, 2002). WNV infection cycle follows 
the mosquitoes' activity, which usually starts in the spring where mosquitoes are most 
active and abundant. The cycle ends early fall when conditions start to become 
unfavorable and mosquitoes go into diapause.  
1.5. Epidemiology 
 Since the discovery of the virus in the West Nile district of Uganda (1937), major 
outbreaks have occurred all around the world, except for Antarctica (Kramer, 2008). 
From 1937 to 1990s, WNV infected people presented mild symptoms, e.g. fevers. 
Starting from 1990s, the frequency of outbreaks and number of cases presenting severe 
neurological symptoms, e.g. viral encephalitis, significantly increased. In Romania 
(1996–1997) an outbreak of WNV caused over 500 clinical cases with 10% of cases 
ending in fatalities (141). In Israel (2000), 417 cases were reported with 317 of the 
patients being hospitalized and 35 of them dying (case fatality rate 8.4%) (Weinberger, 
2001). Along with these two cases, Algeria (1994), Morocco (1996), Tunisia (1997, 
2003), Czech Republic (1997) reported WNV disease (Hayes, 2005). 
 The first documented occurrence of WNV in the Western hemisphere was in 1999 
in New York City (United States (US)), speculated introduction from a single point, 
spreading throughout the eastern states along with westward migration, reaching as far as 
North Dakota in 2001 and California in 2002 (Petersen, 2003). Since the introduction of 
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WNV (1999-2012), over 37,000 cases of WNV infection have been reported (1,549 
deaths) with 286 people dying in the US in 2012 [Centers for Disease Control and 
Prevention (CDC)]. Along with rapid expansion in the US, other western hemisphere 
countries and continents (e.g. Canada, Mexico, Central America, and South America) 
also reported cases of WNV (Campbell, 2002). In Canada (2001), there were reports of 
infected birds, horses, and mosquito pools with 462 human cases (10 deaths) (Dauphin, 
2004). In Mexico (2002), WNV encephalitis-like symptoms in equine were reported in 
five different Mexican states from the border of Texas along the Gulf of Mexico to 
Southern Mexico (Tabasco) (Estrada, 2003).  
 As previously mentioned, female Culex mosquitoes transmit WNV to primarily 
passerine birds and cycle between each other, with vertebrates an incidental host. For that 
reason, high frequency of WNV transmission to humans directly correlates to the ecology 
and feeding behavior of the infected mosquitoes.  People at risk of WNV infection 
include those living near flooded, high vegetation cover, low population density areas 
which are ideal mosquito habitats (Han, 1999). Rate of infection follows mosquitoes' 
activity with approximately 85% of human infections occurring in August and September 
when mosquitoes are most abundant (Peterson, 2004). Susceptibility increases with age, 
compromised immune systems, or predispositions. 
1.6. Pathogenesis  
 After mosquito inoculation of the WNV through the skin cells, keratinocytes and 
most importantly Langerhan dendritic cells (LDC), get infected and replicate the virus. 
Initial recognition of nucleic acid intermediates by pathogen recognition receptors (PRR) 
(e.g. Toll-like receptors and RIG-like receptors) activates Interferon Regulation Factors 
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(IRF) 3 and 7 for production of type I interferons (IFN) (Diamond, 2003). IFNs work 
together to "interfere" with viral replication by increasing expression of Protein Kinase R 
(PKR) and 2’-5’ oligoadenylate synthetase (OAS) and to warn nearby cells of viral 
infection (major function of INF-γ). Binding of PKR to viral dsRNA activates the 
complex resulting in phosphorylation and inactivation of Eukaryotic Initiation Factor 2α 
(eIF2α), inhibiting translation and leading to apoptosis (Lee, 1994; Szretter, 2011). OAS, 
which also binds to viral dsRNA for activation, converts ATP to 2’-5’oligoadenylate 
resulting in binding and activation of RNAse L. RNAse L cleaves both viral and host 
ssRNA, mRNA, and rRNA inhibiting virus replication and protein expression ending in 
apoptosis of infected cell (Silverman, 2007).  Along with IFN innate response γδ T cells, 
NK cells, and macrophages are drawn toward site of infection for specific effector 
functions.   
 While INF response is occurring, infected LDC migrate to the nearest draining 
lymph node, whose primary function is to uptake and process pathogens (viruses) into 
linear antigens (epitopes) forming antigen presenting complex, better known as Major 
Histocompatibility Complex 1 (MHCI), and display assembled MHCI to B, T, and other 
immune cells for adaptive immune response. It is in the lymph node where initial viral 
amplification occurs, creating a high viremia and allowing easy access into the systemic 
circulation system, spreading to visceral organs where a second round of amplification 
occurs (Lim, 2011). During dispersion, naive B-cells are activated by MHCI containing 
WNV antigen for a primary antibody response (about 4 days into infection), which 
consists of naive B-cell production of low affinity but high avidity IgM functioning in 
enhancement of complement activation and immune complex formation (Samuel, 2006). 
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6-8 days into the infection (in mice), after CD4 T-cell activation and affinity maturation, 
higher affinity IgG antibodies are produced along with CD8+ cytolytic T-cell mediated 
response (Suthar, 2013). If spread of WNV is controlled, symptoms are generally mild 
and neurodisease does not present itself.   
1.7. Neurodisease 
 At high viremia levels of WNV, production of tumor necrosis factor (TNF), 
metalloproteinases (Suthar, 2013) and interleukins (Cho, 2012; Welte, 2011) from 
immune response to periphery infection increases the permeability and chance of WNV 
crossing the Blood-Brain Barrier (BBB) into the brain. The BBB is made up of an 
extracellular matrix, endothelial cells, astroglia, neurons, and pericytes with tight 
junctions making it highly selective to small hydrophobic molecules; blocking access to 
large polar molecules and certain pathogens (Lawther, 2011).  The exact mechanism via 
which WNV travels through the BBB is still unclear, but several theories have been 
presented: (1) a relay infection through choroid plexus epithelial cells, neurons, or 
olfactory bulb; (2) transport through infected immune cells in a “Trojan horse” 
mechanism; (3) or retrograde transport from infected peripheral neurons through their 
axons (Kramer, 2007; Welte, 2011; Lim 2011).  
 After breaching the BBB, infected neurons and other supporting cells contribute 
to the deterioration of CNS causing the inflammatory neurological disease by apoptosis, 
cell necrosis, and bystander cytotoxicity (Lim, 2011; Cho, 2012). Apoptosis is considered 
a normal defense mechanism against tumor cells and virally compromised cells by 
programmed cell death preventing them from spreading to uninfected cells. Apoptosis 
can be induced by CD8 T-cells and can take three mechanisms. The first is 
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perforin/granzyme cytolysis mechanism, which uses perforin to make pores in infected 
cells and transport granzyme B into the target cell. Granzyme B, in a series of signal 
cascades, activates caspase-3 (cysteine-dependent aspartate specific proteases) which 
cleaves the inhibitory site of caspase-activated DNAse (iCAD to CAD) leading to DNA 
fragmentation and apoptosis (Reed, 2000). Fas from infected cells and Fas ligand (fasL) 
from CD8 T-cells bind, activating death domains leading to the caspase-dependent 
apoptosis cascade (Wallach, 1999). The TRAIL dependent pathway has a similar ending 
with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from CD8 T-cells 
binding to Death receptors (DR5) from infected cells and activating caspase-dependent 
apoptosis cascade. Other than CD8 T-cells initiating caspase-dependent apoptosis, WNV 
via NS2B-NS3 can also activate caspase-3 and other non-caspase proteases (Shrestha, 
2012). The second mechanism by which WNV affects the CNS is by cell necrosis from 
extensive budding of WNV progeny losing and compromising membrane integrity. The 
last mechanism involves other cells (neural and non-neural) releasing cytotoxic factors, 
including inflammatory cytokines (T-cell chemoattractant Cxcl10, interleukins (ILs), and 
TNF), near a non-infected neuron resulting in degradation of healthy cells (Cho, 2012). 
The underlying conclusion is that regulation of inflammatory response needs to be 
controlled but can be difficult. For example, a minor inflammatory response results in 
uncontrollable infection, however, a major inflammatory response results in irreversible 
harm of both infected and uninfected neurons. 
1.8. Antibody and Antibody-Based Therapeutics 
 A full IgG antibody is tetrameric protein with two light (25 kDa) and two heavy 
chains (LC and HC, respectively) (75 kDa) with each polypeptide held together by 
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disulfide bonds in the quaternary structure (Wang, 2007).  The LC is made up of the light 
variable (VL) and the light constant (CL) domains. The HC is composed of the heavy 
variable (VH) and three separate heavy constant domains (CH1-3, respectively) (Harris, 
1998). The IgG has two functional regions: the Fab and the Fc region (Figure 1A). The 
Fab region functions in specific antigen recognition and is composed of the LC coupled 
with VH and CH1 domains. The Fc region (CH2-3) is responsible for activation of many 
innate cells to perform specific functions and can also determine degree of antibody 
dependent enhancement (ADE), antibody dependent cell-mediated cytotoxicity (ADCC), 
and complement dependent cytotoxicity (CDC) involvement (Ying, 2012). Researchers 
have taken the variable domains and have created a variety of structural antibodies, such 
as Fab (Figure 1E), and single-chain variable fragments (scFv) (Figure 1C) (Eleniste, 
2013; Re, 1988). 
 
 
 
 
Figure 1: Different Antibody Structures. (A) Full IgG Antibody, (B) tetrameric 
bifunctional mAb (BsAb), (C) scFv, (D) E16 (scFv-CH1-3)2, and (E) Fab 
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Figure 2: Assembly of two scFv (VL8D3-VHE16 and VLE16-
VH8D3) into a diabody. 
1.8.1 E16  
 Currently, the leading monoclonal antibody (mAb) candidate against WNV is a 
humanized murine mAb (Hu-E16), which demonstrates neutralizing activity of WNV 
infection in 90% of mice and hamsters when administered 5 days post inoculation 
(Morrey, 2006; Dowd, 2011). Hu-E16 recognizes and binds to Domain III (DIII) of the 
WNV Envelope (E) protein, specifically residues E302–E309 of the N-terminal region, 
residues E330–E333 (BC), E365–E368 (DE) and E389–E391 (FG) (Nybakken, 2005). As 
previously mentioned, the E protein is a dimer with each monomer made up of three 
domains; DI is responsible for conformational arrangement in low pH endosomes, DII 
provides the fusion between the virus and endosome membranes, and DIII acts as the 
binding receptor to trigger fusion (Oliphant, 2005). E16 functions in opsonization of 
WNV, preventing structural rearrangement of the E protein in the acidic environment 
(Kaufmann, 2006). Consequently, blocking DII fusion and denying the virus access to the 
cytoplasm of the cell where replication and translation occur. This inhibitory step 
contains the virus within the endosome ultimately for lysosomal degradation (Thompson, 
2009). 
1.8.2 8D3  
 The Transferrin 
Receptor (TfR) is highly 
abundant in capillary 
endothelium of the BBB 
and functions in 
transcytosis of transferrin, 
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an iron carrying glycoprotein in blood plasma. 8D3 mAb, initially a rat IgG2a to the 
mouse TfR, mimics the specific binding of transferrin to TfR in mice (Kissel et al., 
1998). Once 8D3-TfR binding occurs, receptor-mediated endocytosis engulfs the mAb 
into the cell. Acidic conditions within the endosome dissociate the mAb from TfR 
binding allowing release of the molecule and transportation across the BBB (Manich, 
2013). Recent studies have shown 90% of the conjugated enzyme to 8D3 that entered the 
brain crossed the BBB into the brain parenchyma (Manich, 2013) with the rest targeting 
the liver and kidneys (Lee, 2000).  Utilization of 8D3 mAb has the potential to carry 
other specific therapeutics across the BBB for treating neuro-pathogens and neurodisease. 
 The current challenge with WNV is that there is no known therapeutic that has the 
capability of crossing the BBB and still be able to retain its therapeutic activity to 
neutralize the virus. For example, E16 mAb has the neutralizing and therapeutic activity 
but does not cross the BBB. A recent study by our laboratory described the ability of 
plants to produce tetrameric bifunctional mAb (BsAb) that are able to recognize two 
different epitopes or binding sites within the Fab region (He, 2014) (Figure 1B). These 
BsAbs have the potential to cross the BBB and neutralize the virus. On the other hand, 
the large size of the molecule could decrease the transportation across the BBB 
membrane, thus decreasing the efficacy of the treatment. In a Dengue study, Brien et al 
utilized diabody structures to synergistically complement two mAb varying avidities to 
all four DV serotypes with result showing specific binding of individual mAb with no 
neutralizing enhancement. A diabody (DiAb) consists of two scFvs containing both 
VH and VL regions of two different mAbs with a short linker attaching each domain 
(Figure 2). To get around the BBB impediment, we constructed a bifunctional diabody 
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coupling the E16 mAb WNV neutralizing activity with 8D3 capability to cross the BBB. 
The molecule was characterized and its bi-specificity was tested for retention of specific 
binding.  
2. Results and Discussion 
2.1 Development of a Diabody-Based Therapeutic to WNV 
2.1.1 Molecular design 
 The assembly of a diabody depends on two separately synthesized scFvs, which 
dimerize to form one molecule with antigen binding sites (Fv) facing away from each 
other. The first scFv contains the 8D3 variable light (VL) and E16 variable heavy (VH) 
domain linked together by a short Gly-Ser linker (GGGSGGGG) to connect and prevent 
intramolecular association. The size of the linker is critical for proper assembly of Fv 
regions. A Kozac sequence is added to enhance translation initiation at the 5’ of the first 
scFv coding sequence and is followed by a leader sequence for protein secretion by 
mammalian cells. After the E16 VH coding region, sequence for a kappa LC derived C- 
terminus pairing domain (FNRGEC) followed by the stop codon is added. The construct 
is surrounded by a HindIII and a NotI restriction site (5' and 3', respectively) for ease of 
cloning (Figure 3A).  The second scFv is composed of the complimentary domains, E16 
VL and 8D3 VH domain also linked together by a Gly-Ser linker. The second scFv also 
has a similar molecular arrangement except for a substitution of the LC pairing sequence 
by an IgG1 hinge-derived pairing domain (VEPKSC) (Figure 3B).  A Sac1 restriction 
site was integrated on the end of the VH sequences of both constructs for exchange of the 
pairing domains. Both constructs were cloned into both pcDNA3.1/Hygro (+) and 
pcDNA3.1-zeo (+) vectors for mammalian cell expression.  
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 The design will seek to improve CNS penetration while maintaining WNV 
neutralizing activity by reducing the size of the molecule into a diabody format. 
Theoretically, the small size of the diabody allows for several advantages including ease 
of production and enhanced ability to pass the BBB. The transferrin mechanism allows 
for a one way passage through the BBB further supporting entrance into TfR saturated 
areas. On the other hand, lack of an Fc region makes purification difficult and 
glycosylation impossible. Also the small size of the molecule could result in rapid 
clearance from the blood through the kidneys meaning a higher concentration might be 
needed to have a comparable therapeutic effect as the full antibody.  
 
 
 
Figure 3: Schematic of E16-8D3 diabody gene constructs; (A) 
VL8D3-VHE16-FNRGEC, (B) VLE16-VH8D3-VEPKSC, (C) VLE16-
VH8D3-FNRGEC, and (D) VL8D3-VHE16-VEPKSC 
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2.1.2 Molecular Cloning 
2.1.2.1 Liquid Culture 
 The E16-8D3 DiAb constructs genes (VL8D3-GS linker sequence-VHE16 -
FNRGEC and VLE16- GS linker sequence-VH8D3-VEPKSC) were synthesized, cloned 
into pJ201 cloning vector, and transformed into DH10B Escherichia coli (E. coli) strain 
by DNA2.0. Both DH10B strains were grown in 3 mL of sterilized Luria- Bertani (LB) 
medium (1% tryptone, 0.5% yeast extract, and 0.5% NaCl), plus the addition of 100 
µg/ml kanamycin at 37°C in a shaker (300 rpm) for 16 hours.  
2.1.2.2 DNA Isolation  
 After 16 hours, the 3 mL of DH10B culture were centrifuged in a microfuge in 
1.5 mL increments for 30 seconds at 12 kG. The supernatant was removed with the pellet 
resuspended in 50 µl of TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and vortexed until 
the pellet is resuspended. 300 µl of NS (0.1 N NaOH, 0.5% SDS, and sterile water) was 
added and gently inverted four times to lyse the cells releasing the gene of interest (GOI) 
containing plasmid. 200 µl 7.5 M ammonium acetate was immediately added (within a 
minute after adding NS), mixed and incubated for 5 minutes on ice to neutralize the 
reaction. After the time had elapsed, the sample was centrifuged (12 kG) at 4 °C for 5 
minutes. The resulting supernatant was transferred to clean tube. 330 µl of isopropanol 
was added, incubated at room temperature (RT) for 3 minutes, and microfuged (RT) for 
10 minutes at 12 kG to precipitate plasmid DNA. The supernatant was removed and the 
pellet was washed with 70% ethanol. After the wash, the DNA pellet was left to dry until 
the all of the ethanol evaporated. The DNA was then resuspended in 25 µl of sterilized 
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water. The same protocol was used to isolated pcDNA3.1/Hygro (+) and pcDNA3.1-zeo 
(+) vectors from DH5α (E. coli strain). 
2.1.2.3 Restriction Endonuclease Digestion 
 The isolated plasmid DNA was digested with NotI and HindIII restriction 
enzymes (New England Biolab (NEB)). This was prepared by mixing of 2 μL of 10X 
buffer 2 (500mM NaCl, 100mM Tris-HCl, 100mM MgCl2, 10mM DTT, pH 7.9@25°C), 
13 μL of the isolated DNA, 2 μL of Bovine Serum Albumin (10 mg/ml), 1 μL of RNAse 
A (10 mg/ml), and 1 μL of each restriction enzyme into a microfuge tube. The tube was 
picofuged for 3 seconds and placed in an incubator (37 °C) for 90 minutes. 
2.1.2.4 Agarose Gel Electrophoresis of DNA  
 To separate the digested DNA fragments, they were subjected to agarose gel 
electrophoresis. 0.32 grams of agarose was melted in 40 mL of 1× TAE buffer (40 mM 
Tris-HCl, 40 mM acetic acid, 25 mM EDTA pH 8.0) by applying heat (1 minute in a 
microwave). The agarose was poured into a 7×5 cm agarose gel tray with an eight well 
comb and set to solidify.  After the gel solidified, it was placed on electrophoresis tank 
and submerged in 1× TAE buffer. 3 μL of GeneRuler 1 kb Plus DNA Ladder (Thermo 
Scientific) and each of the 20 μL digest were pipetted into individual wells. The gel was 
ran at 80 Volt (constant voltage) for 90 minutes. After the time elapsed, the gel was 
stained with 0.5% ethidium bromide for 10 minutes and destained with DI water for 20 
minutes. After 20 minutes of destaining, the gel was placed in a UV box for analysis and 
excision of appropriately sized DNA fragments. The DNA was then extracted with 
Qiagen QIAquick Extraction kit and resuspended in 20 μL of sterile water. 
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2.1.2.5 DNA Ligation 
 The next step requires the ligation of the DNA insert fragment to the vector. After 
extraction of DNA fragment, an analytical gel (using the same protocol but utilizing a 
subset of extracted DNA) was ran to estimate the concentration of insert and vector by 
comparing the intensity of the DNA bands with those of the molecular weight marker  
(Figure 4A). Depending on the amount of DNA recovered the quantities will vary, but an 
effective ligation recipe consist 1:3 molar ratio of vector to insert, T4 ligation buffer (50 
mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM dithiothreitol, pH 7.5 at 25 °C), and 1 
unit of T4 DNA ligase. The ligation mixture was mixed and incubated (16°C) overnight. 
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2.1.2.6 Electroporation Transformation 
 The newly ligated DNA was transformed into DH5α by electroporation. First, 2 
μL of ligated DNA was mixed with electro-competent cells and incubated on ice for 1 
 
Figure 4: Analytical agarose gels (A) NotI and HindIII restriction enzyme digestion 
inserts and vectors. Lane 1: VLE16-VH8D3-FNRGEC; Lane 2: VL8D3-VHE16-
VEPKSC insert; Lanes 3 and 4: 232 vector; Lane 5 and 6: 263 vector; Lane 7: 
Generuler 1kB Plus DNA Ladder (Thermoscientific). (B) NotI and HindIII 
restriction enzyme digestion of transformants. Lane 1: 458; Lane 2: 459; Lanes 3: 
460; Lane 4: 463. (C) PvuI restriction enzyme digestion of transformants. Lane 1-
4: transformants from figure 4B, respectively; Lane 5: 467; Lane 6: 468; Lane 7: 
469; Lane 8: 470. 
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minute. The mixture was transferred to an ice cold 0.2 cm electroporation cuvette, 
making sure the cells create a circuit between the plates. The cells were pulsed by 
MicroPulser Electroporator (BioRad) at approximately 2.49 kV with a time constant of 
5.5 milliseconds. After the pulse, the cells were immediately transferred into 1 ml of SOC 
media (2% Tryptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 
mM MgSO4, 20 mM glucose) in a round bottom (RB) tube. The cells were incubated at 
37°C with shaking at 250 rpm for 45 minutes, allowing the cells to recover from the 
electric shock. After the 45 minutes of incubating, the cells were concentrated by 
transferring cells to a microfuge tube, centrifuging them at 12 KG for 2.5 minutes and 
removing 800 μl of the supernatant. The cell pellet was then resuspended and spread on 
LB + ampicillin plates (pcDNA3.1/Hygro (+) and pcDNA3.1-zeo (+) vectors carry 
ampicillin resistance marker gene) and incubated for 24 hours at 37°C. 
 Colonies were screened for the expected insert and vector size following steps 
2.1.2.1-2.1.2.4 (Figure 4B). Since the NotI-HindIII digest yielded similar size between 
pcDNA3.1/Hygro (+) and pcDNA3.1-zeo (+), a second restriction enzyme digestion 
(PvuI) was performed to distinguish the two vectors. pcDNA3.1/Hygro (+) contains two 
PvuI restriction sites, while pcDNA3.1-zeo (+) only contains one (Figure 4C). Analytical 
gel demonstrates the expected bands for all strains (Table 1, in Appendix A).  After GOI 
containing plasmids were identified by gel analysis, the DNA insert in these plasmids 
was sequence to confirm the identity of the construct and that no mutations had occurred 
during the cloning process (Figure 5, in Appendix B). Our results clearly indicate that 
we have successfully constructed the intended diabody constructs.  
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2.1.3 Expression in Mammalian Cell Culture 
 After confirmation, the DNA was transformed into mammalian cells and screened 
for expression (performed by Huafang Lai a collaborator in the lab from Arizona State 
University (ASU)). Mammalian cell-produced E16-8D3 DiAb was examined for its 
ability to bind DIII antigen. This mammalian cell experiment was aimed to preliminarily 
test functionality of the diabody design before moving forward in plant expression. Since 
signal peptide should direct DiAb to be secreted out of mammalian cell, the cells were 
pelleted and conditional media which should contain DiAb was kept for assessment to 
DIII binding. We also examine the cell pellets for DiAb. 
2.1.4 Diabody Binding Assay 
 As previously mentioned, the DiAb structure only contains two binding sites (E16 
and 8D3) without an Fc region. This makes their characterization more difficult due to 
lack of secondary detection antibodies that usually bind to the Fc region. The obstacle 
was overcome by binding the DiAb directly to a high-binding ELISA plate. Thereafter, 
DIII was incubated in the wells to bind with exposed E16 sites. A rabbit anti-DIII 
antibody (He, 2014) was used to bind DIII.  Subsequently, an HRP-conjugated goat anti-
rabbit antibody was used for detection. Hu-E16 mAb was used as a positive control. 
While the positive control demonstrated specific DIII binding, no signal was observed 
from either DiAb contained in the conditional media or the cell pellet. To confirm these 
results, DIII was conjugated with a fluorochrome and used for detection of E16 binding. 
Again, no signal was observed. 
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2.1.5 Discussion of Binding Results 
 Here, we synthesized a gene construct for E16-8D3 DiAb for the goal of 
increasing BBB penetration for therapeutic development against WNV neurodisease. 
Constructs were first produced in mammalian cells to test the binding of the molecule 
with the future goal to be expressed in plants. Unfortunately, the E16 moiety failed to 
show any binding to the DIII antigen. We hypothesize the GS linker is not the optimal 
candidate in size which may lead to improper assembly of the E16 binding site unable to 
recognize the WNV DIII. Finding the correct linker size would take empirical 
experimentation, which demands time and resources that are not supported by our current 
funding. Therefore, we put the DiAb strategy on hold and are pursuing an alternative 
strategy in the form of Fabs.  
2.2 Characterization of Other Anti-WNV Antibody Variants and Antigen  
2.2.1 Plant-Produced mAb Therapeutics 
 There are several culture systems for the production of monoclonal antibodies, 
including mammalian, bacterial, and insect cell-based systems (Chen, 2011a). More 
advantageous is the utilization of plant-based expression systems, specifically 
agrobacterium-mediated vacuum infiltrated transient expression, which offers faster 
production times and greater scalability for commercial production. Aside from 
commercial benefits, plants offer greater safety with reduced risk of transmitting human 
pathogens, perform  mammalian-like post-translational modifications (Chen, 2011a; 
Faye, 2010) and have capability of assembling multimeric proteins (Chen, 2009; Huang, 
2010). Several plant produced multimeric proteins include mAbs, virus-like particles 
(VLPs), and subunit vaccines (Lai, 2012; Negrouk, 2005; Chen, 2009) 
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 Historically, people have been afraid that genetically modified organisms (GMOs) 
would contaminate and decrease biodiversity of naturally occurring species. However, 
plant transient expression has minimized public concerns over GMOs due to the 
utilization of non-transgenic plants for production of biologics with transiently transgenic 
plants being stored within a confined area, eliminating exposure to the environment (Lai, 
2012). In the laboratory setting, Nicotiana benthamiana (N. benthamiana) has been the 
main species of plants utilized for transient expression due to flexibility for both small 
scale analytical studies and commercial use, the broad range of expression vectors 
accessible, high biomass/seed bank yield, and extensive use within the scientific 
community (He, 2012). Although, tobacco is frequently used, other plants (such as 
lettuce, potatoes, tomato, etc.) have been used for transient expression (Wrobleski, 2005; 
Negrouk, 2005; Sohi; 2005). 
 Plant transient expression involves delivery of a GOI into the host plant's genome 
for short-term production of the target protein. Delivery of the transgene into plant cells 
is carried out by Agrobacterium tumefaciens (A. tumefaciens) in a process called 
agroinfiltration. The bacterium fills the interstitial space between the mesophyll, 
delivering GOI containing deconstructed viral vectors into the plant cell (Chen, 2011b; 
Leuzinger, 2013). Deconstructed viral vectors, such as MagnICON and geminiviral, 
utilize virus replicative genome without the structural genes necessary for the 
construction or infectivity of a full live virus, allowing larger transgene inserts to be 
expressed (Gleba, 2004). MagnICON expression system is based on the tobacco mosaic 
virus (TMV) and the non-competing potato virus X (PVX) genomes, each consisting of 
three separately housed components: 5' module (pICH15879 (TMV) and pICH21380 
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(PVX)) containing the promoter and other genetic elements, 3' module (pICH11599 
(TMV) and pICH21595 (PVX)) containing the GOI, and integrase module (pICH14011) 
for integration of the 5' and 3' modules (Chen, 2013). Utilization of both TMV and PVX 
vectors depends if target protein contains multimeric subunits. 
 With all the benefits MagnICON expression offers, the production of mAb 
requires 5 A. tumefacien strains to be co-infiltrating at once. Entailing higher control 
parameters for proper expression of both HC and LC, thus increasing the cost to produce 
these molecules. To overcome this hurdle pE16 scFv-CH1-3 was produced in GnGn 
transgenic N. Benthamiana (Figure 1D) with the intention of lowering the amount and 
number of strains of A. tumefaciens being infiltrated into the host plant for better control 
of anti-WNV therapeutic production. pE16 scFv-CH1-3 was characterized and tested for 
proper folding and retention of binding site with SDS PAGE/Western Blot and ELISA 
analysis, respectively. Along with the pE16 scFv-CH1-3, a DIII vaccine was developed in 
hopes to evoke a specific and sufficiently strong immunological response to provide long 
term immunity against WNV disease. DIII was also produced in N. benthamiana and 
characterized utilizing E16 antibody, known to bind to conformational epitopes 
(Nybakken, 2005), as indication of proper folding. Anti-DIII mouse serum was tested to 
see if DIII produced E16 like antibodies. Finding a prophylactic and/or therapeutic 
vaccine candidate for treatment of WNV requires variable attack strategies with a 
production method that is economically viable for meet the demand. Production of 
antibody variants as well as WNV DIII proteins in plant expression systems offers a cost 
effective and scalable option. 
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2.2.2 Methods, Results, and Discussion 
2.2.2.1 Structural Characterization of Plant-Produced E16 scFv-CH1-3 
 pE16 scFv-CH1-3 was expressed in N. benthamiana plants, and purified by protein 
A chromatography. pE16 scFv-CH1-3 and pE16 mAb (positive control) were ran on a 4-
10% SDS PAGE under reducing (5% v/v  -mercaptoethanol) conditions and stained with 
Coomassie Blue (Figure 6A). For Western Blot, pE16 scFv-CH1-3, pE16 mAb, and 
uninfiltrated GnGn leaf extracts (negative control) were ran on a 4-10% SDS PAGE 
under reducing (Figure 6B) and non-reducing (Figure 6C) conditions for 2 hours at 
100V. Gels were transferred to PVDF membrane at 80 mA overnight in 4 °C. After 
transfer, the membrane was blocked with 5% milk in PBST for 2 hours and washed after 
with PBST. Membrane was probed with 1% milk diluted HRP-conjugated goat anti-
human gamma for an hour intended to detect the light and HC, respectively. ECL 
Western blotting detection reagent (ECL) was added to the membrane and developed on 
x-ray film. These results demonstrate that pE16 scFv-CH1-3 was expressed in plants with 
the expected LC and HC components and efficiently assembled into its tetrameric form. 
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2.2.2.2 pE16 scFv-CH1-3 E Protein Binding by ELISA 
 96-well high-binding ELISA plates were coated with 1 μg/mL of WNV E protein in 
0.1 M Na carbonate buffer and incubated for 4 hours at 37 °C. After the time had elapsed, 
the plates were washed three times with PBST (PBS with 0.1% Tween-20) and blocked 
with 5% milk in PBST for an hour at 37°C to reduce non-specific binding. All samples 
(pE16 scFv-CH1-3 GnGn, pHu-E16 (plant-produced, positive control), mHu-E16 
(mammalian cell-produced, positive control), and Hu-IgG Anti-Ebola (negative control)) 
were diluted in the following concentrations (ng/ml): 2000, 1000, 500, 250, 125, 62.5, 
31.25, 15.625 in 1% milk in PBST.  Samples were added to appropriate wells and 
incubated for 2 hours at 37 °C. After a wash step, 50 μL of HRP-conjugated anti-human-
kappa antibody was added as the detection antibody for 1 hour at 37 °C. The ELISA plates 
were then thoroughly washed four times with PBST to remove unbound detection antibody 
   
 
Figure 6: SDS PAGE and Western blot analysis of the pE16 scFv-CH1. (A) Molecular 
weight marker (lane 1), pE16 mAb (lane 2) and pE16 scFv-CH1 (lane 3) were 
separated on SDS-PAGE gels under reducing conditions (lanes 1 and 2) and stained 
with Coomassie Blue. (B and C) uninfiltrated GnGn leaf extracts (lane 1, negative 
control), pE16 mAb (lane 2), and pE16 scFv-CH1 (lane 3) were separated on SDS-
PAGE gels under reducing (B) or non-reducing (C) conditions and transferred onto 
PVDF membranes. The membranes were incubated with a goat anti-human gamma 
chain antibody for detection.  
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and developed with tetramethylbenzidine (TMB) substrate (KPL Inc). To stop the reaction, 
50 μL of 1 M phosphoric acid was added after 2 minutes and read at 450 nm.  ELISA 
analysis revealed similar binding of pE16 scFv-CH1-3 to WNV E protein as those of pHu-
E16 and mHu-E16 (Figure 7). This result demonstrates that pE16 scFv-CH1-3 retains the 
antigen binding specificity of the full pHu-E16 antibody, indicating it is a promising 
therapeutic candidate against WNV infection. 
 
2.2.2.3 Characterizing Plant-Produced DIII Antigen’s Binding to E16 mAb 
 High-binding ELISA plates were coated with of E. coli or plant produced 
(extracts 1 and 2) DIII (1 μg/mL) in 0.1 M Na carbonate buffer and incubated for 4 hours 
at 37 °C, separately. E16 mAb was diluted (1% milk) in following concentrations 
(ng/ml): 2000, 1000, 500, 250, 125, 62.5, 31.25, 15.625 and added in duplicates into 
wells, followed by incubation for 2 hours at 37 °C. Detection was carried out by HRP-
conjugated anti-human-kappa antibody for 1 hour in 37 °C. The plates were developed 
with TMB substrate and 1M phosphoric acid. The plates were read at 450 nm. Results 
show plant-produced DIII specifically recognizes E16 mAb. Since E16 has been shown 
WNV E protein binding by E16 varaints
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Figure 7: Specific binding 
ELISA of pHu-E16 scFv-CH1-3 
to WNV E protein was 
incubated in the sample wells 
coated with WNV E protein and 
detected with an HRP-
conjugated anti-human kappa 
antibody. pHu-E16 and mHu-
E16 were used as positive 
control. pHu-Ebola Gp1 was 
used as a negative control. 
Mean± SD of samples of 
samples from triplicate values. 
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to only recognize properly assembled DIII antigen (Lai 2010), this result indicates that 
plant-produced DIII was properly folded in the tertiary structure (Figure 8).  
 
2.2.2.4 Characterize the Antigenicity of Plant-Produced DIII Antigen by Competitive 
ELISA 
 Plant-produced DIII antigen was examined for its immunogenicity in inducing the 
production of WNV DIII specific antibodies in mice. 25ug of plant-DIII was injected into 
groups of mice with PBS as a negative control. Serum samples were collected 12 weeks 
after the immunization. Two batches of plant-produced DIII were used in the animal 
study. High-binding ELISA plates were separately coated with E. coli or plant produced 
DIII (batch 1 and 2) (at 1 μg/mL) and incubated for 4 hours at 37 °C. After blocking and 
three washes, serum samples from DIII or PBS immunized mice were diluted 1:100 and 
incubated in the wells for 2 hours at 37 °C. Plates were washed and then incubated with 
E16 (32.25 ng/mL) for plant-DIII batch 1 and E. coli DIII-coated wells, and 62.5 ng/mL 
for plant DIII-batch 1-coated wells. Detection and analysis were carried out similarly as 
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Figure 8: Specific binding ELISA of pHu-E16 to plant and E. coli produced DIII. 
Serial dilutions of pHu-E16 were incubated in sample wells coated with plant and E. 
coli produced DIII and detected with an HRP-conjugated anti-human kappa 
antibody. Mean ± SD of samples from duplicate values. 
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ELISAs described above. Inhibition was calculated by the percent difference in OD450 
absorption (formula between anti-DIII or preimmune serum samples and anti-PBS serum. 
Results indicate that antibodies in DIII-immunized serum efficiently compete with pHu-
E16 in binding coated DIII antigen, and in turn, inhibit its binding to DIII by ~50% 
(Figure 9).  This indicates that plant-produced DIII antigen elicited E16 like antibodies in 
mice, suggesting this antigen can be used as a potential vaccine candidate.  
 
 Overall, structural and binding characteristics of pE16 scFv-CH1-3 as well as plant 
produced DIII were tested with western blot and specific binding ELISAs. Proper 
assembly into its tertiary structure was confirmed along with specific binding for both 
pE16 scFv-CH1-3 and DIII, demonstrating plants capacity to produce a great structural 
array of functional proteins. Furthermore, anti-DIII serums from mice presented 
competition (over 40% inhibition) against E16 in binding DIII antigen, indicating plant-
DIII vaccine was able to generate a specific and potentially protective immune response 
in mice. 
 
Figure 9: Competitive ELISA of plant and E. coli produced DIII binding by 
pHu-E16 and antibodies in anti-DIII serum. Plates coated with respective DIII 
were pre-incubated with 1:100 dilution of sera and subsequently with pHu-
E16. Detection was carried out by anti-human kappa antibody. Mean ± SD 
represent triplicate samples. 
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3. Conclusions 
 WNV is a growing epidemic all around the world with no approved prophylactic 
or therapeutic vaccines on the market. Great strides have been made to treat and prevent 
WNV disease especially those that develop into neurological symptoms. E16 mAb is the 
leading candidate able to prevent death up to 5 days after WNV infection (Morrey, 2006; 
Dowd, 2011), however lacks the ability to cross the BBB to neutralize CNS bound WNV. 
The diabody configuration that consists of both E16 and 8D3 scFv moieties was explored 
to enhance BBB penetration of E16. We successfully developed the molecular constructs 
of the diabody. However, further work need to be done to optimize the functionality of 
such design.  Our results also demonstrate that the plant-produced E16 scFv-CH1-3 has 
the specific functionality in recognizing and binding DIII antigen with comparable 
affinities as pHu-E16 and mHu-E16. Also, the DIII-vaccine candidate was demonstrated 
to elicit production of E16 like antibodies that has a high likelihood to prevent severe 
WNV disease. Although, further research is still needed, vast progress has been made for 
the development of a prophylactic vaccine and an efficacious therapeutic against WNV 
with innovative strategies and promising results. 
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CHAPTER 3 
DENGUE VIRUS 
1. General overview 
 Dengue virus, also called break-bone fever and the 5-day or 7-day fever, is known 
as the most encountered Flavivirus in the world. Affecting close to a third of the world's 
population, all four or possibly five (Normile, 2013) distinct enough serotypes (DV 1-4) 
are capable of causing life-threatening disease.  
1.1 Signs and Symptoms  
 Dengue infection can be asymptomatic or manifest itself in Dengue fever (DF) or 
Dengue Hemorrhagic Fever (DHF), which involves a rapid onset of capillary leakage 
leading to Dengue Shock Syndrome (DSS). Severity of DF symptoms usually depends on 
age of the patient and recurrence of inoculation with a different DV serotype. Younger 
children and people who have not had a DV infection often encounter the milder 
symptoms but the disease could still be fatal. Symptoms include high fevers (40 °C), 
headaches, myalgia, arthralgia, nausea, lymphadenopathy, and rash (Whitehorn, 2011). 
High fevers result in dehydration and could cause convulsions or other neurological 
trouble. A severe case of DF presents thrombocytopenia (low platelet counts) and 
leucopenia (low white blood cell count), which can be observed with hemorrhage 
complications usually present in the gums, epistaxis (nose), and gastrointestinal tract. 
Symptoms usually emerge 4-10 days after DV inoculation and last 2-7 days. 
 DHF typically presents itself in people that are immunocompromised and are 
exposed to a second infection with a different DV serotype (Guzman, 2003; Effler, 2005). 
Patients suffering from DHF often present high fevers, severe abdominal pain with 
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persistent/bloody vomit, plasma leakage resulting in high hematocrit concentration 
(increase of 20%), and hepatomegaly. Although, both DHF and DF share certain 
symptoms, severity among them differs. Symptoms usually progress together leading to 
dehydration, fluid accumulation, and eventually circulatory system failure reaching the 
critical stage (DSS). At that time, temperatures usually decrease (37.5-38 °C) and 
depending on degree of capillary permeability patient might recover or go into shock. 
After DSS episode, the patient usually dies within 12-24 hours or recovers with 
appropriate intravenous fluid replacement therapy. Patients experiencing DSS have a 
20% mortality rate in places with insufficient resources or expertise but can be as low as 
1% when treatment is applied early (Anne, 2013). 
1.2 Treatment and Prevention 
 Currently, there are no approved vaccines or therapeutic treatments for DV 
infections; although, there are some promising vaccine candidates in phase 2 of clinical 
studies. These vaccines aspire to produce immunogenicity against all four DV serotypes 
(tetravalent), while decreasing DHF/DSS susceptibility to second DV different serotype 
infection (del Angel, 2013) and being relatively inexpensive to produce due to 
socioeconomic status of endemic areas. The leading candidate (phase 3 clinical trials) is a 
Chimeric vaccine (known as ChimeriVax or CYD TDV), which swapped the preM and E 
genes of yellow fever 17D virus for those of DV 1-4 (Guy, 2011). Other candidates 
include live attenuated, inactivated, and subunit (protein/DNA/viral-vector) vaccines with 
decreasing immunogenicity response, respectively (Webster, 2009; Lee 2012). Until 
approval of a specific and effective vaccine or therapeutic treatment, the recommended 
treatment regime consists of rest, plenty of water and paracetamol for fever and pain 
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alleviation. Preventative measures involve mosquito control strategies by environmental 
control (minimizing mosquito breeding areas), biological control (predation), and if 
necessary chemical control (insecticides) (WHO, 2014).  
1.3 Life cycle 
 Dengue virus is transmitted primarily by Aedes genus mosquitoes with Aedes 
aegypti (A. aegypti) being the most prominent and other mosquitoes (e.g. Aedes 
albopictus) less frequent vectors. Aedes aegypti is highly successful in urbanized areas 
utilizing both man-made and natural sites as breeding areas (Rott, 2010).  These 
mosquitoes are highly resourceful vectors with immature development occurring in man-
made containers (e.g. jars, tires, flowerpots, cans) and adult females residing inside 
houses where they feed exclusively on human blood. For one gonotrophic cycle female 
mosquitoes require multiple blood meals. Due to this necessity and behavior, A. aegypti 
is able to transmit DV to multiple human hosts (Mosquitoes, 2009). DV cycles between 
the vector to humans and other non-human primates with vertical transmission to 
mosquito progeny.  An uninfected A. aegypti can become infected by feeding on a blood 
meal with high titers of DV; in humans high titers develop 4-7 days post inoculation. This 
results in replication of the virus in the epithelial cells of the midgut and eventual spread 
to the salivary glands where it can infect the next blood meal after an extrinsic incubation 
time of 10-14 days, due to inefficient replication in A. aegypti (Dengue, 2009). 
1.4 Epidemiology 
 The first documented cases of Dengue goes back to the Chin Dynasty (265-420 
A.D.) believed to be attributed to flying insects from "poisoned water" (Gubler, 1998). 
Since then, the virus has been spread to more than 100 countries in the tropical and 
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subtropical areas of the world (e.g. Southeast Asia, Latin America, the Caribbean, and 
Mediterranean). Annually, there are ~50 to 100 million reported cases of infection per 
year with 500,000 of them developing DHF symptoms (Guzman, 2010). The 
geographical range of the virus is attributed to the spread of the vector, Aedes genus 
mosquitoes, which dispersed from Africa to Asia and later to the rest of the world 
through increased globalization and global travel (Simmons, 2012). It is thought that 
rapid development and weak infrastructure in healthcare increases the fitness of A. 
aegypti mosquitoes by providing a breeding sites and dense population of humans to feed 
on. Although, these mosquitoes are adapted for highly dense urban settings, there has 
been a movement toward rural areas due to improper vector control. 
 In Southeast Asia and the Pacific, more than half of the world's population is at 
risk of DV infections (leading cause of death in children) with several epidemics already 
occurring in tropical areas (e.g. Indonesia, Thailand, Cambodia) and spreading to 
deciduous areas (e.g. Bangladesh, India, etc). It is important to mention that all four 
serotypes are native in this region (DV-1 (1977), DV-2 (1981), DV-4 (1981), and DV-3 
(1994)) (Gubler, 1998). In Indonesia (2007) and western pacific countries (2001-2008) 
150,000 and approximately 1 million cases were reported, respectively. In both examples, 
fatality rates were no greater than 1% (WHO, 2009). Outbreaks of Dengue have been 
documented in African countries but surveillance data is incomplete.  
 Early eradication campaign of A. aegypti (1960-1970s) slowed the dispersion of 
DV in the Americas. Currently, outbreaks are prominently seen in the tropical regions 
where mosquito control is not maintained (Guzman, 2002; Kay, 2005). Throughout 2001 
to 2007, 30 countries in the Americas reported about 4.3 million cases of dengue 
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infection with 106,037 developing into DHF (fatality rate 1.2%). Brazil, a highly 
urbanized country surrounded by rainforest, reported about 64% of the total dengue 
infections and had the highest fatality rate (WHO, 2009) with 700,000 cases reported per 
year (Figueiredo, 2012). The Andean countries (19%) reported the highest cases of DHF 
(61,341) with Central American (13%), Caribbean (3.9%), and North American (<0.1%) 
reporting lower case numbers (WHO, 2009). Aside from small epidemics occurring in 
Hawaii, most cases of DV infections in North America are imported from travelers.  
 The epidemiology studies (Guzman, 2003; Effler, 2005; Halstead, 2007) in 
Hawaii, Singapore, and Cuba show outbreaks of Dengue in island systems. Within these 
virgin systems, first exposure (DV-1 in Cuba) generally resulted in the mild disease of 
DF.  After 4 years, a different serotype (DV-2) was introduced and resulted with higher 
incidences of DHF/DSS, especially previously exposed to DV-1, with long-interval 
secondary exposures resulting in more severe symptoms. Also, there were higher 
incidences of DHF/DSS in infants that were never exposed to DV but where the mother 
had been infected and produced antibodies against the specific DV serotype (Whitehorn, 
2011; Kliks, 1988). Conclusions from these results support the theory of ADE and 
progressive loss of cross neutralizing antibodies with different serotypes of dengue. 
1.5 Pathogenesis 
 Mosquito inoculation of DV eventually infects and replicates in LDC, which 
transports the DV antigens to the nearest lymph node, presenting to and activating 
passing innate cells. Innate cells (specifically monocytes and macrophages) travel to the 
infection site in attempts of killing the virus and any infected cells, but instead get 
infected by the virus (Ubol, 2010; Murphy, 2011).  Throughout the innate immune 
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response infected cells produce interferons and other cytokines to prepare defenses of 
other cells causing initial DV symptoms. Infected innate cells disseminate the virus 
throughout the body, while infecting other cells and increasing DV viremia. After 
activation of adaptive immune system, CD8+ cytolytic T-cells along with B-cell 
production of IgM and IgG antibodies help kill and neutralize specific DV serotype.  
Both memory B and CD4+ T-cells recognize and can neutralize to homotypic (same 
serotype) DV infections for a lifetime and heterotypic (different serotype) DV infections 
for 3-4 months (Beltramello, 2010; Anne, 2013).  
 After the short period of protection, secondary heterotypic DV infections have 
been seen to produce more cases of the severe symptoms (DFH/DSS) in a phenomenon 
coined ADE (Halstead, 1988). In secondary heterotypic DV infections, antibodies from 
the first infection are able to recognize and bind to DV but fail to destroy the virus. These 
sub-neutralizing antibodies facilitate binding to monocytes through the Fcγ regions of the 
antibodies and Fcγ receptor (FcγR) on immune cells, increasing virus uptake and 
replication, consequently increasing severity of disease (Wan, 2013). Similarly, 
activation of memory T-cells generates a non-specific inflation of cytotoxic T-cell 
response incapable of clearing current DV serotype infection. In addition, heighten T-cell 
activation results in an exaggerated cytokine production, such as IFNγ, TNFα, and IL 2, 
6, 8, and 10 (Guzman, 2002), which is suspected of increasing vascular permeability and 
tissue damage leading to plasma leakage.   
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Figure 10: Plant and mammalian glycosylation 
forms for pE60 in transgenic plants.  (A) wild type 
GnGnXF6, (B) GnGn, (C) GnGnF6, (D-F) high 
mannose forms Man7-9, (G) AA, (H) AAF6.  
 
1.6 Antibody-Based Therapeutics Against DV: E60 
 Initially raised against WNV, E60 mAb demonstrated cross reactivity and 
neutralizing activities against DII 
fusion loop on the E protein of 
DV (Oliphant, 2006; Williams, 
2013; Brien, 2013). The fusion 
loop is highly conserved among 
all DV serotypes (Gromowski, 
2008; VanBlargan, 2013). Early 
work modified E60 from a mouse 
IgG2a mAb into an E60 chimeric 
human IgG1 mAb with a mutation in position 297 (asparagine to glutamine) in Fcγ 
region (Balsitis, 2010). Administration of E60-chimeric Hu-IgG1 mAb (50 μg) in 
addition to anti-DV1 serum (to simulate secondary heterotypic DV exposure) 48 hours 
after initial infection resulted in 80% survival in mice demonstrating therapeutic efficacy 
(Balsitis, 2010). Similar to E16 mAb, E60 inhibits fusion of the virus to the endosomal 
membranes after initial binding to receptors for endocytosis (Costin, 2013; Lok 2008). 
This inhibitory step prevents the virus from gaining access to the translational and 
replicative machinery of the cell by holding it within the endosome (Thompson, 2009). 
 The glycosylation patterns and structure of an immunoglobulin molecule have a 
great impact on its effector function (Arnold, 2007). Specifically, different N-
glycosylation patterns to the Fcγ region of CH2 of IgG1 can determine its CDC and 
ADCC, and ADE activity (Zheng, 2011). Aglycosylated mAb can prevent the binding of 
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IgG1 to the FcγR, and in turn, eliminating ADE. However, aglycosylated mAb also lost 
all its CDC activity that may be necessary for its full therapeutic activity. Furthermore, 
aglycosylation can also cripple the stability of the mAb, thus decreasing the half-life of 
the molecule (Zheng, 2011; Kayser, 2010). Wild type (WT) and glycoengineered N. 
benthamiana plant lines were used to test the hypotheses that specific glycosylation 
patterns can reduce or eliminate ADE response; while maintaining the necessary CDC 
activity for mAb efficacy against DV.  Analyzing effects of glycosylation of IgG on 
ADCC/CDC activity will also provide answers for the basic question of how 
carbohydrate moieties affect antibody effector functions. Thus, different glycoforms of 
E60 including WT GnGnXF3, GnGn, GnGnF6, high mannose, AA, AAF6 are being 
produced in N. benthamiana plants (Figure 10). Plant-produced E60 was characterized as 
well as investigated for specific binding (in vitro and in vivo) to E protein and 
neutralization activity with the aim of developing an effective of anti-DV therapeutics 
with enhanced safety. 
2. Results and Discussion 
2.1 Molecular Design 
 The humanized E60 VH coding sequence was optimized with tobacco codons and 
fused with human IgG1 CH1-3 sequence and VL to human kappa CL. Both molecular 
constructs were preceded with a Kozac and leader sequence to enhance translation and 
for ER targeting, respectively. In both constructs EcoRI and BamHI (5' and 3', 
respectively) restriction sites bordered the gene for ease of sub-cloning. The longer HC 
was cloned into 3' TMV vector while the shorter LC was cloned into 3' PVX vector for 
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Figure 12: Analytical agarose gel of 
constructed E60 IgG1 cut with EcoRI 
and BamHI. Lane 1: E60 IgG1 HC in 3' 
TMV; Lane 2: E60 IgG1 LC in 3' PVX. 
 
MagnICON plant expression due to 3'TMVs has a stronger promoter compared to 3'PVX 
(Figure 11).  
 
 
2.2 Molecular Cloning 
 Overlap PCR was utilized to add in 
the EcoRI site, Kozac sequence, start 
codon, intronless signal peptide to the 5’ 
end, and a NheI site to the 3’ end of both 
E60 VH (pCI neo-chE60hG1) and E60 VL 
(pCI neo-chE60Lc). PCR products were 
cloned into Topo2.1 vector (antibiotic 
resistant against ampicillin) and 
transformed into DH5α (Topo VH and 
Topo VL). 
The construction of the LC involved a 
three way ligation between TOPO VL (EcoRI/ NheI), plant codon optimized human 
Kappa LC (NheI/BamHI) and the 3' PVX vector (EcoRI/BamHI). For the HC, the three 
Figure 11: Schematic of pE60 gene constructs. (A) pE60 HC-IgG1, and (B) pE60 LC-
IgG1. 
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way ligation was between TOPO VH (EcoRI/ NheI); plant optimized human IgG1 CH1-3 
region (NheI/BamHI) and the 3' TMV vector (EcoRI/BamHI). The only difference in the 
ligation method is the molar ratio (1:2:2, vector: insert 1: insert 2). Once the constructs 
were verified through gel analysis (Figure 12) and sequence confirmation (Figure 13, in 
Appendix C), the DNA was transformed into A. tumefaciens (electroporator settings: 
2.20 kV and 5.80 milliseconds) (new strains 485 (E60 HC) and 486 (E60 LC)). 
2.3 Plant expression  
 All MagnICON modules were cultured individually in YENB media (0.75% 
Bacto yeast extract, 0.8% Nutrient Broth, and pH 7.5) plus appropriate antibiotics in RB 
tubes at 30 °C in a shaker (300 rpm). Depending on the type of agroinfiltration (syringe 
or vacuum) and the amount of plants that are going to be infiltrated, volumes will vary 
with optimal concentrations determined by empirical experimentation (He, 2014). For the 
following pE60 analysis results, the A. tumefaciens concentration used was 0.12 for each 
construct, totaling a final concentration of 0.60 OD600. Both WT and GnGn six week old 
plants were infiltrated for p E60 expression. After 4 days post infiltration (dpi), necrosis 
of the leaf became apparent so samples were gently cut from infiltrated leaf tissue. For 
small scale estimation of expression levels, samples were weighed to 0.3 gram leaf fresh 
weight (LFW), placed in microfuge tubes with a scoop of copper beads for plant leaf 
homogenization, and were immediately stored in -80 °C until usage. For larger scale 
extraction, leaves were either stored in -80 °C or processed with 30 min of harvest.   
2.3.1 Extraction of pE60 from N. benthamiana Leaves 
 Leaf samples were homogenized at 4 °C (to reduce protein degradation) in 
extraction buffer (100mM Tris-HCl, pH 8.0, 150mM NaCL, 1mM PMSF, tablet protease 
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inhibitor cocktail) at a 1:1.5 ratio of LFW (g) to buffer (mL). Samples were repeatedly 
centrifuged at 10 kGs for 15 minutes with supernatant transferred to clean microfuge 
tubes until extract was clear. Clear extracts were used to initially estimate total protein 
with Bradford protein assay, characterize pE60 with Western Blot analysis, and binding 
specificity with E protein binding ELISA. pE60 was purified by ammonium sulfate 
precipitation and protein A chromatography (by  Matthew Dent from ASU). Purified 
samples were used for yeast binding (performed by Huafang Lai) and neutralization 
assays (performed by Dr. Michael Diamond lab from Washington University School of 
Medicine). 
2.3.2 Expression Level Quantitation by ELISA 
 To analyze the total soluble protein we utilized a Bradford protein assay. Regular 
(non-high binding) ELISA plates were loaded with diluted plant extracts (40x) with 5 μL 
going into each well. BSA (positive control) was diluted with PBS (137mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4,) at the following concentrations (μg/ml): 
150, 100, 50, 25, 12.5, 6.25, 3.125, and 0. The Bradford reagent was also diluted 
(specified by the manufacturer) and 160 μL was added to each well. The samples were 
read at 450 and 595 nm with the ratio (595/450) plotted against the known concentrations 
of BSA (μg/mL). The crude pE60 ratio was 0.05725 which when calculated suggests the 
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total protein concentration of pE60 is about 4 mg/mL (Figure 14). 
 
2.4 Structural and Functional Characterization of Plant-Produced E60. 
2.4.1 Proper Assembly of pE60 Analyzed by SDS PAGE and Western Blot 
 The pE60 samples were ran on a 4-10% SDS PAGE under reducing and non-
reducing conditions for 2 hours at 100V. Gels with purified pE60 were stained with 
Coomassie Blue (Figure 15A) and gels loaded with crude pE60 extracts were transferred 
to PVDF membrane at 80 mA overnight in 4 °C. After transfer, the membranes were 
blocked with 5% milk in PBST for 2 hours. After blocking, the membranes were washed 
with PBST and probed with 1% milk diluted HRP-conjugated goat anti-human kappa LC 
(Southern Biotech) for an hour intended to detect the light chain. ECL reagent was added 
and developed on x-ray film (Figure 15B). Our results indicate that E60 was produced in 
plants with the expected HC and LC, and they efficiently assemble into the tetrameric 
 
 
Line of Best Fit 
Formula 
A B R² 
 Y=A*X+B 0.001944 -0.02177 0.98 
  
Figure 14: Bradford assay OD595/450 versus BSA 
concentration. Dilutions of BSA as well as crude pE60 
extract (1:40 diluted) was pippetted into plate. Total 
protein was detected with Bradford's Reagent. Mean ± 
SD represents duplicate samples. 
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structure. In addition, they can be purified to high homogeneity by a two-step processing 
scheme. 
  
2.4.2 Specific Binding to its Antigen Measured by ELISA  
 To test if pE60 specific binding to its antigen, high binding ELISA plates were 
coated with 1 μg/mL of purified WNV E protein in carbonate buffer (100 mM Na2CO3, 
pH 9.6) overnight at 37 °C for 4 hours. The plates were washed three times with PBST 
and blocked with 5% milk in PBST.  Plant extracts were diluted 1:2, 1:4, 1:8, 1:16, 1:32, 
and 1:64 with 1% milk in PBST. Purified plant E16 ((ng/ml): 2000, 1000, 500, 250, 125, 
62.5, and 31.25) was used as a positive control to generate the standard curve and a 
generic IgG was used as the negative control.  All samples were incubated for 2 hours at 
 
 
Figure 15: Characterization of pE60 with SDS PAGE 
(A) and Western blot (B) under reducing (R) and non-
reducing (NR) conditions. (A) Molecular weight marker 
(lane 1), flow through (lane 2), pE60 (lane 3), mE16 
(lane 4), mE16 (NR) (lane 5), and pE60 (NR) (lane) 
were ran on SDS-PAGE gel and stained with 
Coomassie Blue. (B) pE60 (NR) (lane 1), negative 
control (lane 2), mE16 (NR) (lane 3), pE60 (R) (lane 4), 
negative control ( lane 5), and mE16 (R) (lane 7) ran 
on SDS PAGE and transfer to PVDF. The blot was 
incubated with HRP-conjugated goat anti-human kappa 
for detection. 
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Figure 16: Specific binding ELISA of pE60 to WNV E 
protein. Serial dilutions of pE60 were incubated in sample 
wells coated with WNV E protein and detected with an 
HRP-conjugated anti-human kappa antibody.pHu-E16 was 
used as positive control and a generic human IgG was used 
as a negative control. Mean ± SD of samples from 
triplicates values.  
37 °C. After washing, the 
plates were incubated with 
HRP-conjugated anti-
human-kappa LC 
antibody. The plates were 
then developed with TMB 
substrate, stopped with 1 
M phosphoric acid, and 
read at 450 nm. The 
results show specific 
binding of pE60 mAb to 
WNV E protein. It appeared that the binding affinity of pE60 was lower than that of pHu-
E16 mAb (Figure 16). However, it is most likely that this discrepancy is due to the 
different concentration of the two mAbs used in the assay.     
2.4.3 Specific Binding to its Antigen Measured by Flow Cytometry 
 To confirm the ability of pE60 in recognize DV DII in its native conformation, as 
expressed in DV, recombinant yeast cells expressing DV2 DI-DII were taken from the 
log phase and incubated in tryptophan free media containing 2% galactose to induce 
expression of DI-DII. Positive yeast cells were incubated in mE60 (positive control), 
pE60 (WT and GnGn), stained with Alexa Fluor 467 (Invitrogen), and subject to analysis 
by BD FACS Calibur flow cytometer. The yeast binding assay demonstrated that pE60 
(WT and GnGn) has the same specific binding as mE60 (Figure 17). 
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Figure 18: Neutralization of DV by pE60 variants. DV 
was incubated with serial dilutions of mE60 as positive 
control, pE60 (WT and GnGn) and used to infect Vero 
cells. Resulting plaques were analyzed by focus 
reduction assay and Biospot analysis. 
 
2.4.4 Neutralization of DV by plant-produced E60 
 DV2 was initially 
incubated with a serial 
dilution of pE60 (WT or 
GnGn) and mE60 
(positive control).  
Uninfected Vero cells 
were incubated in each 
sample, later fixed and 
permeabilized.  Plaques 
were quantified by focus 
reduction assay and biospot analysis. The neutralization assay demonstrated that pE60 
(WT and GnGn) as well as mE60 were able to neutralize DV with full neutralization 
occurring when concentrations were above 1000 ng/mL (Figure 18). 
  
 
Figure 17: Binding of E60 mAb to DI-DII displayed on yeast cell surface. 
Recombinant yeast cells were incubated in (A) PBS, (B) mE60 (positive 
control), (c) WT pE60, and (D) GnGn pE60. After incubation, yeast cells were 
stained with an Alexa Fluor -467 and analyzed with FACS Calibur flow 
cytometer. 
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3. Conclusions and future directions 
 Herein, we produced E60 chimeric human IgG1 mAb against all serotypes of DV 
in two different glycoforms (WT and GnGn) utilizing plant transient expression in N. 
benthamiana. Our results to date show that the feasibility of utilizing plant expression 
systems to produce great quantities (> 500ug/g FLW) of different glycoforms of pE60. In 
addition, both glycoforms of pE60 were able to assemble efficiently and demonstrated 
specific binding to the fusion loop on DII and while retaining neutralization activity seen 
in the mammalian cell-produced counterpart. Almost full neutralization of DV2 was 
achieved at concentration greater than 1000 ng/mL for both pE60 and mE60. These 
results indicate that plant-produced E60 is a promising candidate for developing 
efficacious therapeutics against DV. The next step would be to test the different 
glycoforms for ADCC, CDC, and ADE response in vitro and ultimately in vivo in a 
mouse model to demonstrate its enhanced safety over the mammalian cell-produced E60. 
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APPENDIX A 
 
TABLE 1: DIABODY GENE CONSTRUCTS 
58 
 
 
Gene Construct  Strain number  Expected Size when cut with 
NotI/HindIII (Base Pair 
(bp))  
VL8D3-VHE16-FNRGEC 
(Hygro)  
458  881 and 5529  
VLE16-VH8D3-VEPKSC 
(Hygro)  
459  878 and 5529  
VL8D3-VHE16-FNRGEC (Zeo)  460  881 and 4947 
VLE16-VH8D3-VEPKSC (Zeo)  461  878 and 4947  
VL8D3-VHE16-VEPKSC 
(Hygro)  
467  881 and 5529  
VLE16-VH8D3-FNRGEC 
(Hygro)  
468  878 and 5529  
VL8D3-VHE16-VEPKSC (Zeo)  469  881 and 4947 
VLE16-VH8D3-FNRGEC (Zeo)  470  878 and 4947  
pcDNA3.1/Hygro (+)  232  5529  
pcDNA3.1-zeo (+)  263  4947  
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APPENDIX B 
FIGURE 5: SEQUENCE COMPARISON OF E16-8D3 DIABODY CONSTRUCTS 
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APPENDIX C 
FIGURE 13: SEQUENCE COMPARISON OF E16-8D3 DIABODY CONSTRUCTS 
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A) pE60 IgG1 HV 
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B) pE60 IgG1 LC 
 
  
 
